Minerva Neurosciences | NERV - Capitaux D'Emprunt





Capitaux D'Emprunt Changement Date
Acadia Pharmaceuticals USD 0 0 2025-03
Adma Biologics USD 192.84M 745K 2026-06
ALKERMES USD 1.48B 7.23M 2026-06
Alterity Therapeutics Limited AUD 43.68K 59.53K 2025-12
AstraZeneca USD 26.01B 46M 2026-06
BioCryst Pharmaceuticals USD 395.4M 203K 2026-06
Bristol-Myers Squibb USD 42.09B 59M 2026-06
Cipla INR 3.82B 840.2M 2026-03
Clal Biotechnology ILS 25.96M 18.48M 2023-12
Compugen USD 0 0 2024-12
CSL USD 10.42B 273M 2025-12
Eli Lilly USD 47.86B 8.49B 2026-06
GlaxoSmithKline GBP 13.95B 65M 2026-06
Grifols EUR 9.95B 722.93M 2025-12
Halozyme Therapeutics USD 1.94B 1.79M 2026-06
Ionis Pharmaceuticals USD 1.91B 6.62M 2026-06
J&J USD 37.34B 183M 2026-06
Merck USD 51.08B 4.41B 2026-06
Minerva Neurosciences USD 0 86.58M 2024-09
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novartis USD 37.49B 42M 2026-06
Novavax USD 246.3M 200K 2025-12
Pfizer USD 60.5B 70M 2026-06
Roche Holding CHF 25.22B 2.21B 2026-06
Sanofi EUR 14.65B 806M 2026-06
Takeda JPY 4.42T 50.32B 2026-06
Vanda Pharmaceuticals USD 3.15M 3.15M 2024-12